Medicine
Glipizide 5 mg tablet
Glipizide 5 mg tablet is a generic prescription medicine for oral use, made by 24 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store below 30°C (86°F).
Key facts
- Active ingredient (INN)
- Glipizide
- Brand
- Sold under the generic name
- Strength
- 5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 71400 tablets, 100 tablets, 500 tablets and 167 more
- Manufacturers
- A-S Medication SolutionsOxford PharmaceuticalsAdvagen PharmaAiPing PharmaceuticalApotexActavis PharmaRising Pharma HoldingsANI PharmaceuticalsLegacy Pharmaceutical Packaging24 labelers on the register
- Origin register
- US FDA, United States
- Storage
- Store below 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10BB07 Glipizide
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 27 February 1995
- Identifiers
- RxCUI 310488, 310490, 379804 +1DailyMed set ID ad55dfd7-ffb5-478a-aa84-1009fa921e22, aa1b16bf-e01c-d539-e053-2995a90a2735, d91d021f-f644-eac7-e053-2995a90a81c4 +37NDC 0591-0460, 50268-361, 51407-620 +37Application ANDA074223, ANDA075795, ANDA074497 +4
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
A sample of 40 packs from 24 labelers. The register lists 170 packs for this generic presentation, and we confirm the exact pack on the quote.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 71400 tablet in 1 case | 11788-117-00 | AiPing Pharmaceutical | 9 October 2026 |
| 100 tablet in 1 bottle | 11788-117-01 | AiPing Pharmaceutical | 9 October 2026 |
| 500 tablet in 1 bottle | 11788-117-05 | AiPing Pharmaceutical | 9 October 2026 |
| 1000 tablet in 1 bottle | 11788-117-10 | AiPing Pharmaceutical | 9 October 2026 |
| 100 tablet in 1 bottle, plastic | 0591-0460-01 | Actavis Pharma | 27 February 1995 |
| 500 tablet in 1 bottle, plastic | 0591-0460-05 | Actavis Pharma | 27 February 1995 |
| 1000 tablet in 1 bottle, plastic | 0591-0460-10 | Actavis Pharma | 27 February 1995 |
| 1000 tablet in 1 bottle | 72888-116-00 | Advagen Pharma | 3 October 2023 |
| 100 tablet in 1 bottle | 72888-116-01 | Advagen Pharma | 3 October 2023 |
| 500 tablet in 1 bottle | 72888-116-05 | Advagen Pharma | 3 October 2023 |
| 30 tablet in 1 bottle | 72888-116-30 | Advagen Pharma | 3 October 2023 |
| 1000 tablet in 1 bottle | 62559-315-10 | ANI Pharmaceuticals | 31 May 2022 |
| 100 tablet in 1 bottle | 60505-0141-0 | Apotex | 25 September 2002 |
| 1000 tablet in 1 bottle | 60505-0141-1 | Apotex | 25 September 2002 |
| 500 tablet in 1 bottle | 60505-0141-2 | Apotex | 25 September 2002 |
| 18000 tablet in 1 bottle | 60505-0141-8 | Apotex | 25 September 2002 |
| 30 tablet in 1 bottle | 68645-574-54 | Legacy Pharmaceutical Packaging | 25 September 2002 |
| 90 tablet in 1 bottle | 69584-309-09 | Oxford Pharmaceuticals | 18 September 2026 |
| 100 tablet in 1 bottle | 69584-309-10 | Oxford Pharmaceuticals | 1 May 2025 |
| 180 tablet in 1 bottle | 69584-309-18 | Oxford Pharmaceuticals | 18 September 2026 |
| 360 tablet in 1 bottle | 69584-309-36 | Oxford Pharmaceuticals | 18 September 2026 |
| 500 tablet in 1 bottle | 69584-309-50 | Oxford Pharmaceuticals | 1 May 2025 |
| 1000 tablet in 1 bottle | 69584-309-90 | Oxford Pharmaceuticals | 1 May 2025 |
| 100 tablet in 1 bottle | 64980-696-01 | Rising Pharma Holdings | 30 October 2026 |
| 1000 tablet in 1 bottle | 64980-696-10 | Rising Pharma Holdings | 30 October 2026 |
| 500 tablet in 1 bottle | 64980-696-50 | Rising Pharma Holdings | 30 October 2026 |
| 30 tablet in 1 bottle | 50090-0502-0 | A-S Medication Solutions | 29 June 2016 |
| 60 tablet in 1 bottle | 50090-0502-1 | A-S Medication Solutions | 29 June 2016 |
| 100 tablet in 1 bottle | 50090-0502-2 | A-S Medication Solutions | 29 June 2016 |
| 90 tablet in 1 bottle | 50090-0502-3 | A-S Medication Solutions | 29 June 2016 |
| 180 tablet in 1 bottle | 50090-0502-4 | A-S Medication Solutions | 29 June 2016 |
| 30 tablet in 1 bottle | 50090-6473-0 | A-S Medication Solutions | 11 May 2023 |
| 60 tablet in 1 bottle | 50090-6473-1 | A-S Medication Solutions | 11 May 2023 |
| 100 tablet in 1 bottle | 50090-6473-2 | A-S Medication Solutions | 11 May 2023 |
| 90 tablet in 1 bottle | 50090-6473-3 | A-S Medication Solutions | 11 May 2023 |
| 180 tablet in 1 bottle | 50090-6473-4 | A-S Medication Solutions | 11 May 2023 |
| 90 tablet in 1 bottle | 50090-6975-0 | A-S Medication Solutions | 22 December 2023 |
| 30 tablet in 1 bottle | 50090-7755-0 | A-S Medication Solutions | 5 November 2025 |
| 60 tablet in 1 bottle | 50090-7755-1 | A-S Medication Solutions | 5 November 2025 |
| 100 tablet in 1 bottle | 50090-7755-2 | A-S Medication Solutions | 5 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 8 May 1984 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Glipizide
Clinical summary
Glipizide is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available as tablets and extended-release tablets for oral use. MedsAcross supplies Glipizide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about GlipizideFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Glucotrol XL prescribing information (Roerig) · U.S. National Library of Medicine, DailyMed
Need Glipizide 5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.